EMEA-001911-PIP02-22-M01 - paediatric investigation plan

Inebilizumab

Key facts

• Invented name:
  Uplizna
• Active Substance:
  Inebilizumab
• Therapeutic area:
  Nervous system disorders
• Decision number:
  P/0206/2024
• PIP number:
  EMEA-001911-PIP02-22-M01
• Pharmaceutical form(s):
  Concentrate for solution for infusion
• Condition(s) / indication(s):
  Treatment of myasthenia gravis
• Route(s) of administration:
  Intravenous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  14/06/2024

Decision

P/0217/2024: EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for inebilizumab (Uplizna) (EMEA-001911-PIP03-23-M01)

Adopted